The Experts in Animal Health

Brakke Consulting’s
Animal Health News & Notes for September 30, 2022
Copyright © Brakke Consulting
Editor: Lynn Fondon DVM MBA


Brakke Consulting News
Cancer in Dogs and Cats – Now Available

Earnings News

Other News
At One Ventures
Dalan Animal Health
Dentalis Animal Health
Diamond Pet Food
Intersand Canada Group
Invictos Orthopedics
LeeO Precision Farming
Norwest Venture Partners
PetSmart Veterinary Services
Scratch Financial
Sentrx Animal Care
SK Telecom
Starfish Vision
Tiba Biotech
Veritas Veterinary Partners
Veterinary Angel Network for Entrepreneurs
Veterinary Surgical Specialists
Vetoquinol (Simplera Otic)
Vetoquinol (Flexadin)
VMG Partners

Now Available

Did you know that cancer is the #1 cause of death in adult dogs?  It’s also a leading health concern of dog owners.  So how is cancer addressed by the veterinary profession, and what kind of market is there for veterinary cancer therapies?

Brakke Consulting’s new 2022 Cancer in Dogs and Cats report includes information on the incidence, diagnosis, and treatment of the common veterinary cancers.  It covers currently approved veterinary therapies and those in development, as well as estimates of the numbers of pets treated.


The study includes a survey of over 350 general veterinary practitioners about incidence of cancer and frequency of treatment; as well as a survey of 1,000 pet owners to determine what they are willing to pay to treat a pet with cancer.

The report is now available for $8,500. For more information or to order the report, please contact Dr. Lynn Fondon at







  • Neogen Corporation announced results of the first quarter of its 2023 fiscal year, which ended August 31. Revenues were $132 million, an increase of 3% compared to the prior-year quarter. Net income was $5.2 million, adversely impacted by $13.7 million of professional fees and other deal-related expenses incurred in connection with Neogen’s combination with 3M’s Food Safety business; prior-year 1Q net income was $17.1 million. Revenues for the company’s Animal Safety segment were $67.7 million, an increase of 3% (+4% currency-adjusted). (Seeking Alpha)


  • Animalcare reported results for the first half of 2022. Revenues were GBP 38.3 million ($41.4 million), a 2% decline compared to the prior-year period (flat on a currency-adjusted basis). Underlying EBITDA was down 5% to GBP 8 million ($8.6 million). (IHS Markit Connect – subscription)



  • Zoetis announced the launch of Solensia (frunevetmab), the first FDA-approved treatment for osteoarthritis (OA) in cats. Solensia is a first-in-class monoclonal antibody that provides pain relief for cats with OA for up to a month with a single injection. (company announcement)
  • The FDA announced it has approved Vetoquinol‘s Simplera Otic Solution (generic florfenicol, terbinafine, mometasone furoate), a single dose treatment with a 30-day duration of effect for otitis externa (outer ear infection) in dogs associated with susceptible strains of yeast and Staph bacteria. Simplera Otic Solution, a generic equivalent of Elanco’s Claro, is now available to veterinarians in the USA. (FDA, company press release)
  • Vetoquinol USA announced the launch of five new Flexadin products: Flexadin Young Dog; Flexadin Young Dog Mini; Flexadin Advanced for Cats; Flexadin Adult Dog & Cat; and Flexadin Advanced Extra Strength. (company press release)
  • The FDA announced it has approved Bimeda Animal Health Ltd’s SpectoGard (spectinomycin sulfate), the first generic spectinomycin sulfate injectable solution for the treatment of bovine respiratory disease (pneumonia) associated with Mannheimia haemolytica, Pasteurella multocida, and Histophilus somni. (FDA)
  • TheraVet announced it has entered into an exclusive distribution agreement with Invictos Orthopedics LLC, under which Invictos will promote and distribute the full line of Biocera-Vet products throughout the USA. (Businesswire)
  • Vaxxinova announced it has acquired Epitopix, a poultry and livestock vaccine research company. Financial terms were not disclosed. (com)
  • Diamond Pet Food announced a $259 million investment to build a new 700,000-square-foot plant in Indiana. (GlobalPets)
  • Animal health veterans and human dental experts have combined and formed Dentalis Animal Health, a start-up company dedicated to the development of superior oral health care products for companion animals, currently developing non-invasive tartar removal products, using an exclusive demonstrated patented technology. The company currently has three products are in development. (company press release)
  • Maev, a human-grade raw dog food company, announced it has raised a $10 million Series A round of funding led by VMG Partners. (axios – subscription)
  • Dalan Animal Health, Inc. announced the close of a $3.55 million seed financing round led by At One Ventures and Veterinary Angel Network for Entrepreneurs (VANE). The company will use the new funding to bring to market the world’s first insect vaccine for honeybees for vaccination against American Foulbrood. (Benzinga)
  • Innovafeed announced it has raised $250 million in a Series D funding. The insect producer will increase production capacity in France and accelerate its international expansion in the US by constructing a new plant in partnership with ADM in Illinois. (GlobalPets)
  • US firm Tiba Biotech announced a collaboration with the New South Wales (NSW) government in Australia to develop next-generation mRNA veterinary vaccines. The five-year, multi-million-dollar agreement will see US business Tiba focus on developing the vaccines to tackle emergency animal diseases that threaten Australia’s livestock industry and domestic food security. (IHS Markit Connect – subscription)
  • PetSmart Veterinary Services announced the grand opening of its first veterinary hospital in Peoria, Arizona, after announcing its new franchising model. (Vet Advantage)
  • Veritas Veterinary Partners, a national network of over 100 leading specialty and emergency veterinary care providers, has acquired Veterinary Surgical Specialists (VSS) based in Southern California. Financial terms were not disclosed. (DVM360)
  • Scratch Financial announced it has closed on $35 million in Series C funding. The round was led by Norwest Venture Partners. Scratch’s payment and financing tools assist pet owners in covering the cost of pet care. (Veterinary Practice News)
  • StadiumSpot, a manufacturer of licensed sporting pet products, announced it has acquired Moonshine and Starfish Vision, two of the category’s largest and oldest licensed sporting pet product brands. Financial terms were not disclosed. (Pet Business)
  • NETHERLANDS Merck Animal Health announced it has completed a minority investment in Dutch firm LeeO Precision Farming, a technology firm that offers farmers, producers and retailers a cloud-based, real-time digital swine traceability solution to continuously track and analyze pigs from birth throughout their life. Merck will also assume distribution of LeeO’s digital swine traceability solution in selected markets over the coming months. Financial terms were not disclosed. (Businesswire)
  • UK Virbac announced that Suprelorin (deslorelin) 4.7mg Implants for Dogs, a reversible alternative to surgical castration, is now licensed in the UK for use in male cats from 3 months of age. The implant – which lasts at least 12 months – provides temporary infertility and suppression of urine odor and of sexual behaviors such as libido, vocalization, urine marking, and aggressiveness in intact male cats. (org)
  • AUSTRALIA Sentrx Animal Care and Provet announced that Provet will be the exclusive distributor representing Sentrx’s patented crosslinked Hyaluronic Acid BioHAnce brand of ophthalmic products in in Australia. (company press release)
  • CANADA Intersand Canada Group announced it has acquired the manufacturing assets of VersaPet. The new plant now allows Intersand to increase its production capacity by more than 100,000 metric tons per year, thus positioning the company as the second largest manufacturer of private label cat litter products in North America. Financial terms were not disclosed. (Pet Product News)
  • KOREA SK Telecom (SKT) announced the launch of X Caliber, Korea’s first AI-based veterinary X-ray image diagnosis assistance service. (com)
  • UK ProtonDx, a spin-out from Imperial College in London, announced it has been awarded GBP 365,000 ($391,000) in government funds to develop porcine lung disease diagnostic tests. The target porcine lung infections include porcine respiratory disease complex (PRDC). The grant will allow ProtonDx to adapt its automated “lab-on-a-chip” technology  to create an automated diagnostic that will be able to simultaneously test the eight major bacterial and viral pathogens seen in PRDC. (IHS Markit Connect – subscription)


Animal Health Jobs 

How difficult is it for your company to find the talent that you need?  Chances are, it has become more difficult.  It’s challenging for HR and talent leaders.

Animal Health Jobs wants to hear your thoughts on the hiring market. We’re conducting a survey to gain a deeper understanding on hiring in the Animal Health Industry. We will share these animal health and nutrition industry specific results with you in future blogs and white papers at Animal Health Jobs.

Once you complete the survey, you will be entered into a drawing for one of twenty- $10 Starbucks e-gift cards. The survey link will close Friday, October 7th. You will notified by email before the gift card is sent

CLICK HERE to take the survey!

  • US – VETERINARY CREDENTIALS Colorado has signed into law a bill that will regulate the state’s veterinary technicians. Beginning January 1, 2023, only veterinary technicians registered with the Colorado Department of Regulatory Agencies can use the title veterinary technician. Professionals not interested in registration can continue doing their job as long as they don’t use the title. (Vet Advantage)
  • US – LARGE ANIMAL VETERINARY MEDICINE USDA’s National Institute of Food and Agriculture announced at the end of August that it had awarded $3.2 million in grants to support rural veterinary services through the Veterinary Services Grant Program. Grants were awarded to projects that aim to support rural veterinarians and improve care for farm animals. Several individual veterinary practices also received grants. (Vet Advantage)
  • CANADA – RABIES Canada has banned importation of dogs, including dogs for sale or adoption, from more than 100 countries where authorities say rabies risks are high. Some advocacy organizations have condemned the policy, but the Canadian VMA says it will protect dogs and people. (AVMA SmartBrief – TheGlobeandMail)


If you read this newsletter each week, you know we’ve been following the progress of Zoetis’ Solensia (frunevetmab) into the US market.  Although approved by the FDA in January 2022, it was just launched in the US by Zoetis this past week.

Solensia opens finally opens the osteoarthritis treatment segment for cats in the US; the product is predicted to be a blockbuster (>$100 million) when it matures.  Since the market for OA products in dogs has been a major driver of growth in the animal health industry over the past 20+ years, launch of the first OA treatment safe and effective for cats will have a strong additional effect.  Today Zoetis remains exclusively positioned to supply monoclonal antibody products in veterinary medicine.  We also expect to see the launch of Zoetis’ Librela (bedinvetmab) in the US to treat OA in dogs sometime in the next 12 months.

Market research conducted by Brakke in late 2021 showed >90% of veterinarians are likely to use Solensia, primarily in cats with OA that aren’t being treated with a prescription medication.  We believe that Zoetis has worked hard this year to create awareness of OA in cats.  Today this feline market is substantially underserved, so the Solensia launch will cause significant market expansion.  The OA market in dogs is of course quite crowded already, so the effect of the Librela launch may be less impactful, but still significant.  Time will tell.

Jim Kroman


Last week’s question dealt with use of video in corporate intros and recruiting.  It seems that 50% of our respondents have already begun to use video in this way, with mostly good result (32%) or “too early to tell (14%).”  Only 4% have used video with poor results.  Another 25% are planning to use it, and the last 25% have no interest to do so.  Something tells us that may change in future!

This week

This week, we’re asking you for your prediction of your business results in 2022 now that the 3rd quarter is coming to a close.  With ¾ of the year behind us, you likely have a pretty good idea of the finishing quarter.
How much sales growth will your business show for 2022?